CWC Advisors LLC. bought a new stake in shares of INVO Bioscience, Inc. (NASDAQ:INVO – Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 100,477 shares of the company’s stock, valued at approximately $71,000. CWC Advisors LLC. owned 2.64% of INVO Bioscience as of its most recent filing with the Securities and Exchange Commission.
INVO Bioscience Price Performance
NASDAQ INVO opened at $0.84 on Friday. INVO Bioscience, Inc. has a 1-year low of $0.63 and a 1-year high of $3.50. The business’s fifty day moving average price is $0.78 and its 200-day moving average price is $0.87.
INVO Bioscience (NASDAQ:INVO – Get Free Report) last posted its earnings results on Wednesday, August 14th. The company reported ($0.62) earnings per share for the quarter. The business had revenue of $1.84 million during the quarter.
INVO Bioscience Company Profile
INVO Bioscience, Inc, together with its subsidiary, a healthcare services fertility company, provides assisted reproductive technology solutions worldwide. It offers INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman’s body. The company was founded in 2007 and is based in Sarasota, Florida.
See Also
- Five stocks we like better than INVO Bioscience
- What is a Secondary Public Offering? What Investors Need to Know
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- What Investors Need to Know About Upcoming IPOs
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- Ride Out The Recession With These Dividend Kings
- MarketBeat Week in Review – 10/21- 10/25
Want to see what other hedge funds are holding INVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for INVO Bioscience, Inc. (NASDAQ:INVO – Free Report).
Receive News & Ratings for INVO Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INVO Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.